CJC-1295 no-DAC

Mechanism

Binds the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs as an agonist, causing release of growth hormone, which in turn raises hepatic IGF-1. Without the DAC albumin-binding tail it is cleared quickly, with a half-life on the order of 30 minutes, so the growth hormone rise is a short pulse rather than a sustained elevation.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Pulsatile GH release
• Sleep and recovery
• Daily-cadence GHRH

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

6.7 +/- 0.5 minutes (human, IV) — study. value is for [D-Ala2]GHRH(1-29)-NH2, the one substitution shared with mod GRF 1-29; no PK study of the full tetrasubstituted analogue is on file.

Storage

not on file — no stability record on file — no ProSpec or pharmacopoeial datasheet for the no-DAC (Mod GRF 1-29) form; do not carry over the DAC figures.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.4 (GHRH analogues, e.g. CJC-1293, CJC-1295). the list The list does not distinguish DAC from no-DAC; both are CJC-1295.

The half-life on file is 7 min, measured intravenously. At the fastest schedule this record states — every 8 h — each dose has fallen to under 0.1% of its own peak by the time the next is given. Nothing accumulates, and there is no loading phase to run. The record gives 7 to 21 times a week; the fastest is drawn.

The half-life was measured by a route this is not given by. That makes it a lower bound rather than an estimate: absorption from an injection site goes on supplying the blood after an intravenous bolus would have cleared, so the real curve is flatter and lasts longer than the one drawn here. It is never shorter.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Water retention

  Reportedonset: First weeksreported reversible

• Flushing after injection

  Reportedonset: Minutesreported reversible

• Numbness or tingling in extremities

  Reportedonset: Weeksreported reversible

Literature on file 8

• review or editorial
  Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulling Back the Curtain on Taboo Practices (Substance Use & Misuse 2016, cited 37x) graded on: indexed as "Review" - secondary literature, not a study — “Review”
• review or editorial
  Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• review or editorial
  The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• review or editorial
  Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (Drug Testing and Analysis 2010, cited 55x)

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data stacking ubiquitous nothing on file either way

  A 100-250 mcg dose stacked with equal-dose ipamorelin, injected before bed on an empty stomach, is circulated as the standard protocol, run 5 days on and 2 off.

  250 mcg CJC-1295 + 250 mcg Ipamorelin

  On the record Dosing on file is 100-300 mcg daily for the no-DAC form; no record covers the stack, the 5-on/2-off pattern, or any combined-dose synergy.

  Source 1 · Source 2

• unverified community data benefit common nothing on file either way

  Guides claim the stack produces 2-3x greater GH output than either peptide alone because two receptor systems converge.

  The result is synergistic -- 2-3x greater GH output than either alone.

  On the record Nothing on file quantifies combined GH output; the record holds each compound's own GH-release evidence separately.

  Source 1

• unverified community data stacking common nothing on file either way

  Guides state both peptides can be drawn into one syringe and injected together, and vendors sell pre-mixed 5mg/5mg blend vials.

  Both peptides can be drawn into the same syringe

  On the record No co-formulation compatibility record exists on file for this pair — exactly the gap the co-formulation check is meant to name.

  Source 1

• unverified community data timing common nothing on file either way

  An 8-weeks-on, 8-weeks-off cycle is circulated to 'let IGF-1 normalize' and prevent receptor desensitisation.

  8 weeks on, 8 weeks off

  On the record No cycling or desensitisation record exists on file for CJC-1295 no-DAC.

  Source 1

Identity

PubChem CID 91971820 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 91971820, the identifier on this record.

Molecular weight

3647.2

Molecular formula

C165H269N47O46

CAS number

446262-90-4

PubChem CID

91971820

InChI key

ZUQGTWKGESAQCD-ZGFIGYLBSA-N

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N

InChI

InChI=1S/C165H269N47O46/c1-22-87(15)130(209-137(233)92(20)185-148(244)116(76-127(225)226)196-136(232)89(17)183-138(234)99(168)73-95-44-48-97(217)49-45-95)160(256)204-115(74-94-36-25-24-26-37-94)154(250)211-132(93(21)216)162(258)195-108(54-57-123(171)221)145(241)205-120(80-215)158(254)200-114(75-96-46-50-98(218)51-47-96)153(249)192-105(43-35-66-182-165(177)178)141(237)191-102(40-28-31-62-167)146(242)208-129(86(13)14)159(255)202-109(68-81(3)4)147(243)184-90(18)135(231)189-106(52-55-121(169)219)143(239)198-112(71-84(9)10)151(247)206-118(78-213)156(252)186-91(19)134(230)188-103(41-33-64-180-163(173)174)140(236)190-101(39-27-30-61-166)142(238)197-111(70-83(7)8)150(246)199-110(69-82(5)6)149(245)194-107(53-56-122(170)220)144(240)201-117(77-128(227)228)155(251)210-131(88(16)23-2)161(257)203-113(72-85(11)12)152(248)207-119(79-214)157(253)193-104(42-34-65-181-164(175)176)139(235)187-100(133(172)229)38-29-32-63-179-124(222)60-67-212-125(223)58-59-126(212)224/h24-26,36-37,44-51,58-59,81-93,99-120,129-132,213-218H,22-23,27-35,38-43,52-57,60-80,166-168H2,1-21H3,(H2,169,219)(H2,170,220)(H2,171,221)(H2,172,229)(H,179,222)(H,183,234)(H,184,243)(H,185,244)(H,186,252)(H,187,235)(H,188,230)(H,189,231)(H,190,236)(H,191,237)(H,192,249)(H,193,253)(H,194,245)(H,195,258)(H,196,232)(H,197,238)(H,198,239)(H,199,246)(H,200,254)(H,201,240)(H,202,255)(H,203,257)(H,204,256)(H,205,241)(H,206,247)(H,207,248)(H,208,242)(H,209,233)(H,210,251)(H,211,250)(H,225,226)(H,227,228)(H4,173,174,180)(H4,175,176,181)(H4,177,178,182)/t87-,88-,89+,90-,91-,92-,93+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,129-,130-,131-,132-/m0/s1

Classified as

GHRH Receptor Agonismmechanism

Most records filed under the growth hormone heading act either here or at the ghrelin receptor, and knowing which one tells you what a study actually measured: the pituitary's output, not a hormone that was injected.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• CJC-1295 no-DAC
• CJC-1295 (no DAC / Mod GRF 1-29)
• cjc 1295 without dac
• cjc no dac
• cjc 1295 without dac peptide

Listed prices 230

What 136 shops we track listed for CJC-1295 no-DAC, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record